NCT06816017 2025-06-16A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)Hoffmann-La RochePhase 1 Withdrawn
NCT05259397 2023-03-08PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)PfizerPhase 1 Withdrawn
NCT04109092 2020-12-14A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102Eisai Inc.Phase 1 Withdrawn
NCT04089163 2020-03-30A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)Tocagen Inc.Phase 1 Withdrawn
NCT02471495 2018-05-07RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)Medical Enterprises Europe B.V.Phase 3 Withdrawn
NCT01284205 2014-08-29First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBCBioniche Life Sciences Inc.Phase 3 Withdrawn